AvenCell Therapeutics

Founded in 2021 and headquartered in Watertown, US, AvenCell Therapeutics, Inc. specializes in immunotherapy solutions.AvenCell Therapeutics specializes in next-generation immunotherapies designed to address hard-to-treat cancers, primarily through its proprietary Universal Switchable CAR and Allogeneic platforms. These innovative therapies leverage advanced technology to enhance the controllability of CAR-T reactivity, ensuring sustained anti-tumor activity while reducing the risks associated with T-effector cell exhaustion and immune suppression. The company's switchable on/off mechanism utilizes universal effector cells combined with Targeting Modules (TMs) for precise targeting of cancer antigens, which is crucial for minimizing adverse effects like cytokine release syndrome (CRS).AvenCell Therapeutics generates revenue primarily through partnerships and collaborations with healthcare institutions, biotechnology firms, and academic entities focused on cancer treatment advancements. These partnerships often involve co-development agreements and clinical trial collaborations where AvenCell's proprietary therapies may be integrated into broader treatment regimens. The company’s flagship offerings, including its Universal Switchable CAR technology, are positioned for use in clinical settings, where pricing structures may include transaction models based on successful outcomes in therapy or milestone achievements in research and development phases. The company plans to introduce new product developments within the next 12-18 months, enhancing its offerings in the oncology space.

1. Series B

   Oct 22, 2024

   Amount

   $112M

   Investors

   Locked